Highlights on immune checkpoint inhibitors in non–small cell lung cancer
The treatment of advanced or refractory non–small cell lung cancer has been historically difficult owing to the lack of studies on effective systemic cure. The progress in lung cancer treatment has plateaued, necessitating new options for additional benefits. Immune checkpoint proteins are co-inhibi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IOS Press
2017-03-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317695013 |